Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 54, 2024 - Issue 4
49
Views
0
CrossRef citations to date
0
Altmetric
Topics in Xenobiochemistry

Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations

, , , , &
Pages 171-181 | Received 01 Jan 2024, Accepted 17 Mar 2024, Published online: 02 Apr 2024
 

Abstract

  1. Cefaclor is a bactericidal antibiotic recommended for treating diverse types of infections. This review aims to comprehensively assess the pharmacokinetic (PK) data on cefaclor in humans.

  2. Google Scholar, PubMed, Cochrane Library, and EBSCO databases were systematically performed to identify all the relevant studies containing at least one reported PK parameter of cefaclor.

  3. Cefaclor shows the linear PK profile as the area under the plasma concentration-time curve from 0 to t (AUC0-t) and maximum plasma concentration (Cmax) increase in a dose-dependent manner. The AUC0-t of cefaclor in the rice diet was found to be higher than that of bread food, i.e. 19.9 ± 2.6 ug/ml.hr vs 15.4 ± 4 ug/ml.hr. The AUC in paediatrics during the fed state was significantly higher compared to that in adults. Patients with renal impairments showed a Cmax 2.2 times higher than that of normal subjects. A significant increase in Cmax was depicted among individuals following a vegetarian diet in comparison with the non-vegetarian diet. Moreover, cefaclor exhibits time-dependent killing above the minimum inhibitory concentration (MIC < 2 ug), favouring its use in treating infections caused by specific pathogens.

  4. This systematic review summarises all the reported PK parameters of cefaclor in healthy and diseased subjects in the literature. This data can help practitioners in adjusting cefaclor doses among different diseases and populations to avoid drug interactions and adverse effects.

Authors’ contributions

Conceptualisation: T.S, A.Z; methodology: T.S, A.Z, I.I, F.A; formal analysis and investigation: I.I, H.S, writing – original draft preparation: T.S, A.Z, H.S, M.F.R; writing – review and editing: I.I, H.S, supervision: M.F.R. All authors have made substantial contributions to the design, extraction, analysis, and interpretation of data and have actively participated in drafting and revising the article. All authors agreed to submit the final version to the journal and agreed to be accountable for all aspects of the work.

Disclosure statement

The authors declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Availability of data and material

All the data used for this publication is either presented in the main article or is available as supplementary information.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.